A Phase 1/2 interventional study of GEN1044 is an immunoglobulin G1 (IgG1) bispecific antibody targeting CD3 and 5T4. in Locally Advanced or Metastatic Solid Tumor(s), Prostate Cancer and Esophageal Cancer, sponsored by Genmab. Terminated at 6 sites in 4 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2023-07-25.
Sponsored by Genmab · Phase 1/2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 3,596 studies in Prostatic Neoplasms with a site in United States — 608 open to participants now, 977 under way, 101 of them phase 3. Prostatic Neoplasms · United States.
Among the 3,596 studies in Prostatic Neoplasms with a site in United States, this one is the 1,502nd largest by enrollment of the 3,023 interventional ones that give a count, is one of 168 that started in 2020, is one of 283 in phase 1/2, and was the 2,545th registered.
7,051 studies on the registry are indexed under Prostatic Neoplasms; 1,579 are open to participants now.
Browse Prostatic Neoplasms studies →608 of the 3,596 studies in Prostatic Neoplasms with a site in United States are open now. Recruiting first, the newest first:
City of Hope Medical Center · Sites in United States
Ages 40–80 · Men only
Fred Hutchinson Cancer Center · Sites in United States
Ages 18+ · Men only
University of Michigan Rogel Cancer Center · Sites in United States
Ages 50–75 · Men only · Healthy volunteers
University of California, San Diego · Sites in United States
Ages 18+ · Men only
Clinton Bahler · Sites in United States
Ages 18+ · Men only
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 1,228 Prostatic Neoplasms studies recruiting now, 927 (75%) set no upper age limit and 76 (6%) stop at 75 or younger; 67 take children under 18; 82 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
3,596 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 898 · Phase 2 1,383 · Phase 3 321 · Phase 4 50
First in 1988; this study’s year is marked. 168 started in 2020.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 48 is below the median of 60 across 5,349 interventional studies indexed under Prostatic Neoplasms.
Median enrollment 48 across the 3,023 interventional studies, 158 across the 478 observational. Of the 2,356 that completed or were terminated, 997 (42%) have results posted.
This tab as a report to print or save as PDF → With an account.
921 of 3,596 have an industry lead sponsor. The 10 most frequent:
Genmab is the lead sponsor of 72 studies on the registry; 15 are open to participants now.
Of its 23 completed or terminated interventional studies of FDA-regulated products, 13 (57%) have results posted.
Genmab has 2 studies filed under Prostatic Neoplasms — fewer than ten, so there is no comparison to draw.
336 of the studies in Prostatic Neoplasms with a site in United States that are under way reach primary completion within a year, 25 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT03348670Phase 3Han Xu, M.D., Ph.D., FAPCR, Sponsor-Investigator, IRB ChairPharmacogenomics IND Commercial SNP Clinical Study - Abiraterone and Single Nucleotide Polymorphisms | 2026-11-18 |
| NCT03767244Phase 3Janssen Research & Development, LLCA Study of Apalutamide in Participants With High-Risk, Localized or Locally Advanced Prostate Cancer Who Are Candidates for Radical Prostatectomy | 2026-12-01 |
| NCT06970847Phase 3Clarity Pharmaceuticals Ltd64Cu-SAR-bisPSMA Positron Emission Tomography: A Phase 3 Study of Participants With Biochemical Recurrence of Prostate Cancer | 2026-12-31 |
| NCT02446405Phase 3University of SydneyEnzalutamide in First Line Androgen Deprivation Therapy for Metastatic Prostate Cancer | 2026-12-31 |
| NCT07427043Phase 3Brigham and Women's HospitalRobotic Opioid-free Prostatectomy Enhanced Strategy (ROPES) | 2026-12-31 |
Add all 336 to your calendar (.ics) → With an account.
Among the 3,596 studies in Prostatic Neoplasms with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The purpose of the trial is to evaluate the safety, determine the recommended Phase 2 dose (RP2D), and assess preliminary clinical activity of GEN1044 in patients with solid tumors.
The trial is an open-label, multi-center safety trial of GEN1044. The trial consists of two parts: a dose-escalation part (Phase 1) and an expansion part (Phase 2a). The expansion part of the trial will be initiated once the RP2D has been determined from Phase 1.
Key Inclusion Criteria:
Dose-escalation part:
Expansion part:
Both parts:
Key Exclusion Criteria (both parts):
Has an uncontrolled intercurrent illness, including but not limited to:
Prior therapy:
Radiotherapy: Radiotherapy within 14 days prior to first GEN1044 administration. Palliative radiotherapy will be allowed.
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Able to have children. For women this usually means from the first period until menopause, unless permanently unable to through surgery; for men, unless permanently sterile. Read who the line is about — participants, women, men, or their partners.
Criteria about it usually ask for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.
Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).
Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Histologically or cytologically confirmed
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Measurable disease
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Reproductive potential
Able to have children. For women this usually means from the first period until menopause, unless permanently unable to through surgery; for men, unless permanently sterile. Read who the line is about — participants, women, men, or their partners.
Criteria about it usually ask for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
NYHA class (heart failure)
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Autoimmune disease
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Allogeneic and autologous transplant
Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Brain metastases
Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).
Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Excipients
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Biological: GEN1044 is an immunoglobulin G1 (IgG1) bispecific antibody targeting CD3 and 5T4.
Drug page: Immunoglobulin G
GEN1044 will be administered intravenously in cycles of 21 days.
Also known as: DuoBody®-CD3x5T4
Number of Participants With Dose Limiting Toxicities (DLTs)
The DLT was defined as Grade (G) \>= 3 cytokine release syndrome or immune effector cell-associated neurotoxicity syndrome; any G3 or 4 hematologic and non-hematologic toxicity (with exceptions defined by the protocol); laboratory abnormality that required clinically significant medical intervention, led to hospitalization, persisted for \>1 week, or resulted in a drug-induced liver injury; G3 or 4 febrile neutropenia; liver toxicity defined by Hy's law; any treatment-related toxicity that caused treatment discontinuation during Cycle 1; or any G5 toxicity.
Time frame: From Day 1 to Day 21 of first cycle
Number of Participants With Treatment Emergent Adverse Events (TEAEs) and Treatment Emergent Serious Adverse Events (TESAEs)
An adverse event (AE) is any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship. An serious adverse event (SAE) is defined as an AE that meets one of the following criteria: fatal or life-threatening; results in persistent or significant disability/incapacity; constitutes a congenital anomaly/birth defect; medically significant (an event that jeopardizes the participant or may require medical or surgical intervention to prevent one of the outcomes listed above \[medical and scientific judgment must be exercised in deciding whether an AE is 'medically significant'\]); required inpatient hospitalization or prolongation of existing hospitalization. A TEAE is defined as an AE occurring or worsening between the first dose of GEN1044 and 30 days after the last dose received.
Time frame: Day 1 through Day 263 (corresponding to maximum observed duration)
Number of Participants With Abnormal Laboratory Values
Number of participants with laboratory values of Grade \>= 3 by NCI-CTCAE v5.0 are reported. The NCI-CTCAE is a descriptive terminology that is used for gradings (Grade 1-5) of Adverse Events (AEs) and of laboratory values; the latter being summarized here. This table reports laboratory values graded only on the numerical value of the reported parameter and is therefore not graded by symptoms or signs. The abnormal laboratory values assessed by the investigator as being AEs are reported also in the AE table. In case a participant reported multiple severity grades for a laboratory value, only the maximum grade was used.
Time frame: Day 1 through Day 263 (corresponding to maximum observed duration)
Number of Participants With Complete Response (CR) or Partial Response (PR)
The radiological evaluation based on Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST v1.1) was performed by investigator using computed tomography (CT) scan/ magnetic resonance imaging (MRI) scan/ positron emission tomography (PET) scan. The CR was defined as disappearance of all target and non-target lesions and all pathological lymph nodes must have decreased to \< 10 mm in short axis. The PR was defined as at least a 30% decrease in the sum of the longest diameters of target lesions taking as reference the baseline sum of longest diameters.
Time frame: Day 1 through Day 233
Number of Participants With Antidrug Antibodies (ADAs) Positive to GEN1044
The detection and titer characterization of ADAs was performed using validated, specific, and sensitive electrochemiluminescence immunoassay (ECLIA) methods. Number of participants with ADA positive post baseline to GEN1044 are reported.
Time frame: Day 1 through Day 263 (predose on Day 1 of Cycles 1, 2, 3, 5, 7, and then on Day 1 of every 4 cycles thereafter, end of treatment [EOT], and 30 days after last study drug)
| Milestone | GEN1044 Doses 0.3/3/3 mg | GEN1044 Doses 1/3/10 mg | GEN1044 Doses 1/3/30 mg | GEN1044 Doses 1/5/30 mg | GEN1044 Doses 1/10/30 mg | GEN1044 Doses 1/5/37.5 mg | GEN1044 Doses 1/5/45 mg | GEN1044 Doses 1/3/60 mg |
|---|---|---|---|---|---|---|---|---|
| Started | 1 | 4 | 7 | 7 | 6 | 2 | 4 | 6 |
| Completed | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Not completed | 1 | 4 | 7 | 7 | 6 | 2 | 4 | 6 |
| Withdrew: Death | 1 | 2 | 3 | 0 | 3 | 0 | 1 | 2 |
| Withdrew: Sponsor decision | 0 | 2 | 3 | 7 | 2 | 2 | 3 | 4 |
| Withdrew: Withdrawal by subject | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 |
| Withdrew: Other | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 |
The DLT was defined as Grade (G) \>= 3 cytokine release syndrome or immune effector cell-associated neurotoxicity syndrome; any G3 or 4 hematologic and non-hematologic toxicity (with exceptions defined by the protocol); laboratory abnormality that required clinically significant medical intervention, led to hospitalization, persisted for \>1 week, or resulted in a drug-induced liver injury; G3 or 4 febrile neutropenia; liver toxicity defined by Hy's law; any treatment-related toxicity that caused treatment discontinuation during Cycle 1; or any G5 toxicity.
| Participants | GEN1044 Doses 0.3/3/3 mg | GEN1044 Doses 1/3/10 mg | GEN1044 Doses 1/3/30 mg | GEN1044 Doses 1/5/30 mg | GEN1044 Doses 1/10/30 mg | GEN1044 Doses 1/5/37.5 mg | GEN1044 Doses 1/5/45 mg | GEN1044 Doses 1/3/60 mg |
|---|---|---|---|---|---|---|---|---|
| Number of Participants With Dose Limiting Toxicities (DLTs) | 0 | 0 | 0 | 0 | 1 | — | 3 | 3 |
An adverse event (AE) is any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship. An serious adverse event (SAE) is defined as an AE that meets one of the following criteria: fatal or life-threatening; results in persistent or significant disability/incapacity; constitutes a congenital anomaly/birth defect; medically significant (an event that jeopardizes the participant or may require medical or surgical intervention to prevent one of the outcomes listed above \[medical and scientific judgment must be exercised in deciding whether an AE is 'medically significant'\]); required inpatient hospitalization or prolongation of existing hospitalization. A TEAE is defined as an AE occurring or worsening between the first dose of GEN1044 and 30 days after the last dose received.
| Participants | GEN1044 Doses 0.3/3/3 mg | GEN1044 Doses 1/3/10 mg | GEN1044 Doses 1/3/30 mg | GEN1044 Doses 1/5/30 mg | GEN1044 Doses 1/10/30 mg | GEN1044 Doses 1/5/37.5 mg | GEN1044 Doses 1/5/45 mg | GEN1044 Doses 1/3/60 mg |
|---|---|---|---|---|---|---|---|---|
| Any TEAE | 1 | 4 | 7 | 7 | 6 | 2 | 4 | 6 |
| Any TESAE | 1 | 1 | 3 | 5 | 4 | 1 | 3 | 5 |
Number of participants with laboratory values of Grade \>= 3 by NCI-CTCAE v5.0 are reported. The NCI-CTCAE is a descriptive terminology that is used for gradings (Grade 1-5) of Adverse Events (AEs) and of laboratory values; the latter being summarized here. This table reports laboratory values graded only on the numerical value of the reported parameter and is therefore not graded by symptoms or signs. The abnormal laboratory values assessed by the investigator as being AEs are reported also in the AE table. In case a participant reported multiple severity grades for a laboratory value, only the maximum grade was used.
| Participants | GEN1044 Doses 0.3/3/3 mg | GEN1044 Doses 1/3/10 mg | GEN1044 Doses 1/3/30 mg | GEN1044 Doses 1/5/30 mg | GEN1044 Doses 1/10/30 mg | GEN1044 Doses 1/5/37.5 mg | GEN1044 Doses 1/5/45 mg | GEN1044 Doses 1/3/60 mg |
|---|---|---|---|---|---|---|---|---|
| Lymphocyte count decreased | 1 | 4 | 7 | 4 | 5 | 2 | 2 | 6 |
| Lipase increased | 0 | 0 | 1 | 1 | 0 | 1 | 2 | 2 |
| Serum amylase increased | 0 | 0 | 1 | 1 | 1 | 1 | 1 | 1 |
| Hypomagnesemia | 0 | 0 | 0 | 0 | 1 | 0 | 2 | 0 |
| Creatinine increased | 0 | 0 | 0 | 1 | 0 | 0 | 1 | 0 |
| Anemia | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 1 |
| Hypokalemia | 0 | 1 | 0 | 0 | 0 | 0 | 1 | 0 |
| Hypoalbuminemia | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 |
| Blood bilirubin increased | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 |
| Gamma-glutamyl transferase increased | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Hypermagnesemia | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 |
| Platelet count decreased | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 |
The radiological evaluation based on Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST v1.1) was performed by investigator using computed tomography (CT) scan/ magnetic resonance imaging (MRI) scan/ positron emission tomography (PET) scan. The CR was defined as disappearance of all target and non-target lesions and all pathological lymph nodes must have decreased to \< 10 mm in short axis. The PR was defined as at least a 30% decrease in the sum of the longest diameters of target lesions taking as reference the baseline sum of longest diameters.
| Participants | GEN1044 Doses 0.3/3/3 mg | GEN1044 Doses 1/3/10 mg | GEN1044 Doses 1/3/30 mg | GEN1044 Doses 1/5/30 mg | GEN1044 Doses 1/10/30 mg | GEN1044 Doses 1/5/37.5 mg | GEN1044 Doses 1/5/45 mg | GEN1044 Doses 1/3/60 mg |
|---|---|---|---|---|---|---|---|---|
| Complete response | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Partial response | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 |
The detection and titer characterization of ADAs was performed using validated, specific, and sensitive electrochemiluminescence immunoassay (ECLIA) methods. Number of participants with ADA positive post baseline to GEN1044 are reported.
| Participants | GEN1044 Doses 0.3/3/3 mg | GEN1044 Doses 1/3/10 mg | GEN1044 Doses 1/3/30 mg | GEN1044 Doses 1/5/30 mg | GEN1044 Doses 1/10/30 mg | GEN1044 Doses 1/5/37.5 mg | GEN1044 Doses 1/5/45 mg | GEN1044 Doses 1/3/60 mg |
|---|---|---|---|---|---|---|---|---|
| Number of Participants With Antidrug Antibodies (ADAs) Positive to GEN1044 | 0 | 3 | 2 | 1 | 0 | 0 | 1 | 1 |
Collected over For AEs: Day 1 through Day 263 (corresponding to maximum observed duration); For All-cause mortality: From date of inform consent form through Day 263 (corresponding to maximum observed duration). Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| GEN1044 Doses 0.3/3/3 mg | 1/1 (100%) | 1/1 (100%) | 1/1 (100%) |
| GEN1044 Doses 1/3/10 mg | 2/4 (50%) | 1/4 (25%) | 4/4 (100%) |
| GEN1044 Doses 1/3/30 mg | 3/7 (42.9%) | 3/7 (42.9%) | 7/7 (100%) |
| GEN1044 Doses 1/5/30 mg | 0/7 (0%) | 5/7 (71.4%) | 7/7 (100%) |
| GEN1044 Doses 1/10/30 mg | 4/6 (66.7%) | 4/6 (66.7%) | 6/6 (100%) |
| GEN1044 Doses 1/5/37.5 mg | 0/2 (0%) | 1/2 (50%) | 2/2 (100%) |
| GEN1044 Doses 1/5/45 mg | 1/4 (25%) | 3/4 (75%) | 4/4 (100%) |
| GEN1044 Doses 1/3/60 mg | 2/6 (33.3%) | 5/6 (83.3%) | 5/6 (83.3%) |
| Event | GEN1044 Doses 0.3/3/3 mg | GEN1044 Doses 1/3/10 mg | GEN1044 Doses 1/3/30 mg | GEN1044 Doses 1/5/30 mg | GEN1044 Doses 1/10/30 mg | GEN1044 Doses 1/5/37.5 mg | GEN1044 Doses 1/5/45 mg | GEN1044 Doses 1/3/60 mg |
|---|---|---|---|---|---|---|---|---|
| Tumour Associated FeverNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 1/1 | 0/4 | 0/7 | 0/7 | 0/6 | 0/2 | 0/4 | 0/6 |
| DiarrhoeaGastrointestinal disorders | 0/1 | 0/4 | 0/7 | 2/7 | 1/6 | 1/2 | 0/4 | 1/6 |
| Cytokine Release SyndromeImmune system disorders | 0/1 | 0/4 | 2/7 | 3/7 | 3/6 | 0/2 | 2/4 | 3/6 |
| PneumonitisRespiratory, thoracic and mediastinal disorders | 0/1 | 0/4 | 1/7 | 0/7 | 1/6 | 0/2 | 1/4 | 2/6 |
| VertigoEar and labyrinth disorders | 0/1 | 0/4 | 0/7 | 0/7 | 0/6 | 0/2 | 1/4 | 0/6 |
| General Physical Health DeteriorationGeneral disorders | 0/1 | 1/4 | 0/7 | 0/7 | 1/6 | 0/2 | 0/4 | 0/6 |
| DizzinessNervous system disorders | 0/1 | 0/4 | 0/7 | 0/7 | 0/6 | 0/2 | 1/4 | 1/6 |
| Pleural EffusionRespiratory, thoracic and mediastinal disorders | 0/1 | 0/4 | 1/7 | 0/7 | 0/6 | 0/2 | 1/4 | 0/6 |
| FatigueGeneral disorders | 0/1 | 0/4 | 0/7 | 0/7 | 1/6 | 0/2 | 0/4 | 1/6 |
| Platelet Count DecreasedInvestigations | 0/1 | 0/4 | 0/7 | 0/7 | 0/6 | 0/2 | 0/4 | 1/6 |
| Event | GEN1044 Doses 0.3/3/3 mg | GEN1044 Doses 1/3/10 mg | GEN1044 Doses 1/3/30 mg | GEN1044 Doses 1/5/30 mg | GEN1044 Doses 1/10/30 mg | GEN1044 Doses 1/5/37.5 mg | GEN1044 Doses 1/5/45 mg | GEN1044 Doses 1/3/60 mg |
|---|---|---|---|---|---|---|---|---|
| ConstipationGastrointestinal disorders | 1/1 | 1/4 | 2/7 | 0/7 | 3/6 | 0/2 | 0/4 | 1/6 |
| DiarrhoeaGastrointestinal disorders | 1/1 | 4/4 | 6/7 | 4/7 | 5/6 | 1/2 | 4/4 | 4/6 |
| DyspepsiaGastrointestinal disorders | 1/1 | 0/4 | 1/7 | 0/7 | 0/6 | 0/2 | 0/4 | 2/6 |
| NauseaGastrointestinal disorders | 1/1 | 3/4 | 5/7 | 4/7 | 4/6 | 1/2 | 3/4 | 5/6 |
| VomitingGastrointestinal disorders | 0/1 | 3/4 | 5/7 | 2/7 | 5/6 | 0/2 | 4/4 | 4/6 |
| FatigueGeneral disorders | 0/1 | 4/4 | 4/7 | 0/7 | 4/6 | 1/2 | 2/4 | 1/6 |
| Cytokine Release SyndromeImmune system disorders | 1/1 | 3/4 | 2/7 | 3/7 | 3/6 | 2/2 | 2/4 | 4/6 |
| HyponatraemiaMetabolism and nutrition disorders | 1/1 | 0/4 | 0/7 | 0/7 | 0/6 | 0/2 | 0/4 | 0/6 |
| Tumour PainNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 1/1 | 0/4 | 0/7 | 0/7 | 0/6 | 0/2 | 0/4 | 0/6 |
| HeadacheNervous system disorders | 1/1 | 1/4 | 0/7 | 0/7 | 0/6 | 1/2 | 1/4 | 2/6 |
Full analysis set included all participants who received at least 1 dose of study drug. Participants were classified according to the assigned dose level cohort.
| Age, Continuous(Years) | GEN1044 Doses 0.3/3/3 mg | GEN1044 Doses 1/3/10 mg | GEN1044 Doses 1/3/30 mg | GEN1044 Doses 1/5/30 mg | GEN1044 Doses 1/10/30 mg | GEN1044 Doses 1/5/37.5 mg | GEN1044 Doses 1/5/45 mg | GEN1044 Doses 1/3/60 mg | Total |
|---|---|---|---|---|---|---|---|---|---|
| Mean | 51.0 ± NA | 61.3 ± 12.89 | 60.4 ± 11.21 | 59.3 ± 8.18 | 62.3 ± 5.79 | 52.0 ± 8.49 | 55.8 ± 15.71 | 54.2 ± 15.29 | 58.4 ± 10.85 |
| Sex: Female, Male(Participants) | GEN1044 Doses 0.3/3/3 mg | GEN1044 Doses 1/3/10 mg | GEN1044 Doses 1/3/30 mg | GEN1044 Doses 1/5/30 mg | GEN1044 Doses 1/10/30 mg | GEN1044 Doses 1/5/37.5 mg | GEN1044 Doses 1/5/45 mg | GEN1044 Doses 1/3/60 mg | Total |
|---|---|---|---|---|---|---|---|---|---|
| Female | 1 | 2 | 3 | 3 | 4 | 1 | 2 | 3 | 19 |
| Male | 0 | 2 | 4 | 4 | 2 | 1 | 2 | 3 | 18 |
| Ethnicity (NIH/OMB)(Participants) | GEN1044 Doses 0.3/3/3 mg | GEN1044 Doses 1/3/10 mg | GEN1044 Doses 1/3/30 mg | GEN1044 Doses 1/5/30 mg | GEN1044 Doses 1/10/30 mg | GEN1044 Doses 1/5/37.5 mg | GEN1044 Doses 1/5/45 mg | GEN1044 Doses 1/3/60 mg | Total |
|---|---|---|---|---|---|---|---|---|---|
| Hispanic or Latino | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Not Hispanic or Latino | 1 | 0 | 2 | 5 | 1 | 0 | 0 | 2 | 11 |
| Unknown or Not Reported | 0 | 4 | 5 | 2 | 5 | 2 | 4 | 4 | 26 |
| Race (NIH/OMB)(Participants) | GEN1044 Doses 0.3/3/3 mg | GEN1044 Doses 1/3/10 mg | GEN1044 Doses 1/3/30 mg | GEN1044 Doses 1/5/30 mg | GEN1044 Doses 1/10/30 mg | GEN1044 Doses 1/5/37.5 mg | GEN1044 Doses 1/5/45 mg | GEN1044 Doses 1/3/60 mg | Total |
|---|---|---|---|---|---|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Asian | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Black or African American | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| White | 1 | 4 | 6 | 5 | 6 | 2 | 4 | 5 | 33 |
| More than one race | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Unknown or Not Reported | 0 | 0 | 1 | 2 | 0 | 0 | 0 | 1 | 4 |
PDFs hosted by the registry, ClinicalTrials.gov.
Ran from Jul 2020 to primary completion in Oct 2021, 15 months.
Results were first posted in Feb 2023, 1 year 3 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is terminated, as verified in Jul 2023. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Immunoglobulin G